IMS 2026 | CARTITUDE-2 Cohort A: ≥5-year remission and survival with cilta-cel in RRMM
During the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK, the Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the long-term outcomes with ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory multiple myeloma (RRMM) in Cohort A of the CARTITUDE-2 trial.
In this interview, Mateos discusses the ≥5-year findings from Cohort A of the phase II CARTITUDE-2 trial (NCT04133636), which evaluated a single cilta-cel infusion in patients with RRMM after 1–3 prior…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.